Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:advantage |
fewer androgenic side effects
|
| gptkbp:compatibleWith |
dietary supplements
|
| gptkbp:contrastsWith |
gptkb:anabolic_steroids
|
| gptkbp:detects |
anti-doping tests
|
| gptkbp:discoveredIn |
1990s
|
| gptkbp:example |
Ligandrol
Ostarine Testolone Andarine |
| https://www.w3.org/2000/01/rdf-schema#label |
SARMs
|
| gptkbp:legalStatus |
banned by WADA
not approved for human use by FDA |
| gptkbp:marketedAs |
research chemicals
|
| gptkbp:mechanismOfAction |
androgen receptor modulation
|
| gptkbp:misuse |
bodybuilding
athletic performance enhancement |
| gptkbp:regulates |
controlled substance in some countries
|
| gptkbp:riskFactor |
unknown long-term safety
|
| gptkbp:routeOfAdministration |
oral
injectable |
| gptkbp:sideEffect |
stroke
liver toxicity increased risk of heart attack testosterone suppression |
| gptkbp:standsFor |
Selective Androgen Receptor Modulators
|
| gptkbp:studiedBy |
pharmaceutical companies
|
| gptkbp:usedFor |
gptkb:bone
muscle growth treatment of muscle wasting |
| gptkbp:bfsParent |
gptkb:SM-113
|
| gptkbp:bfsLayer |
7
|